Electromed (ELMD) investor relations material

Business overview and market position

• Focuses on a single airway clearance product for chronic respiratory diseases, with all manufacturing done domestically and a workforce of about 200 employees.

• Achieved $75 million in trailing 12-month revenue, is profitable, generates cash, and carries no debt.

• Gained greater operating leverage in the past three years, driving improved financial performance.

• Serves a large, underpenetrated market with 1 million diagnosed bronchiectasis patients in the US, but only 150,000 currently using airway clearance technology.

• Total addressable market estimated at $3 billion, with additional opportunity in COPD overlap patients.

Industry trends and growth catalysts

• Recent introduction of US clinical guidelines for bronchiectasis treatment and new FDA-approved drug for inflammation are expected to drive awareness and growth.

• Pharmaceutical companies are investing heavily in market awareness, helping address underdiagnosis and undertreatment.

• Airway clearance is now recognized as a key component of bronchiectasis management, with patients typically using the device twice daily at home.

Product features and patient outcomes

• Product features a patented single-hose, ergonomic, lightweight vest designed for ease of use and daily home treatment.

• Patient journey is closely monitored through assessments and SmartNote reporting, providing feedback to prescribing physicians.

• Demonstrated clinical outcomes include a 57% reduction in antibiotic use, 59% decrease in hospitalizations, and 75% reduction in emergency visits.